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Abstract: The bioactive coating of calcium phosphate cement (CPC) is a promising approach
to enhance the bone-healing properties of bone substitutes. The purpose of this study was to
evaluate whether coating CPCs with bone sialoprotein (BSP) results in increased bone formation.
Forty-five female C57BL/6NRj mice with an average age of six weeks were divided into three groups.
Either a BSP-coated or an uncoated three-dimensional plotted scaffold was implanted into a drilled
2.7-mm diameter calvarial defect, or the defect was left empty (control group; no CPC). Histological
analyses revealed that BSP-coated scaffolds were better integrated into the local bone stock eight
weeks after implantation. Bone volume/total volume (BV/TV) ratios and bone thickness at the
bone–implant contact were analyzed via micro computed tomography (µCT) after eight weeks.
BSP-coated scaffolds and uncoated CPC scaffolds increased bone thickness in comparison to the
control (CPC + BSP: 691.1 ± 253.5 µm, CPC: 603.1 ± 164.4 µm, no CPC: 261.7 ± 37.8 µm, p < 0.01).
Accordingly, BV/TV was enhanced in both scaffold groups (CPC + BSP: 1.3± 0.5%, CPC: 0.9± 0.5%,
no CPC: 0.2± 0.3%, p < 0.01). The BSP coating showed a tendency towards an increased bone thickness
(p = 0.18) and BV/TV (p = 0.18) in comparison to uncoated CPC scaffolds. However, a significant
increase in bone formation through BSP coating was not found.
Keywords: bone sialoprotein; calcium phosphate cements; bioactive coating; 3D printing; mouse
calvarial defect model
1. Introduction
Autologous bone grafting is still considered the gold standard in the treatment of critical-sized
bone defects; it promises bone remodeling after quick graft integration [1,2]. Yet, limited availability
and donor site morbidity point out the necessity for alternatives [3,4]. Extensive research with a
focus on calcium phosphate cement (CPC) scaffolds as bone substitutes has been carried out in
recent years [5]. Their composition is similar to that of mineral bone, and they have shown to be
biocompatible, osteoconductive, and bioactive [6]. Since the development of the spreading technique
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of rapid prototyping (RP) three-dimensional (3D) plotting, the shapes and sizes of scaffolds can be
created specifically. Moreover, the internal pore structure can be adapted, which is important for
osteoconductivity and allows vascular ingrowth. Thus, open macroporous CPC scaffolds can be
created with a compressive strength of 2–5 MPa, which is close to that of human trabecular bone [7,8].
Besides mechanical stability, an osteoconductive matrix, and an osteogenic cell population in the
host tissue, Giannoudis et al. demanded in their diamond concept the presence of an osteoinductive
stimulus [9]. The surface coating of materials with bioactive molecules is one possible way of adding
the osteoinductive element to a scaffold.
Bone sialoprotein (BSP) is a tissue-specific phosphoprotein of the extracellular matrix (ECM)
of bone, and contains several functional domains. Its arginylglycylaspartic acid (RGD) section
represents a cell adhesion motif and is able to interact with the ανβ3-receptor (vitronectin receptor) of
osteoblasts [10,11]. Thus, it regulates the attraction and differentiation of osteoprogenitor cells and
osteoblasts. Coated on titanium, BSP was shown to increase the gene expression level of RUNX2 of
primary human osteoblasts (hOBs) [12]. The BSP coating of CPCs increased osteoblastic viability and
triggered hOB differentiation and spreading, which became apparent in a larger cell area and a reduced
circularity [13]. O’Toole found out that the BSP coating of titanium implants promoted the recruitment
of osteoblastic cells and the formation of osteoid tissue in addition to evidence of neovascularization
in a rat femoral model in vivo [14]. Previous in vivo studies demonstrated improved bone healing
with BSP in critical-sized calvarial defects in rats [15,16]. In a murine BSP gene knockout model
(BSP−/−), the repair of a 1-mm diameter femoral drill hole was delayed respective to wild type [17].
The mineralization of femoral bone was delayed, and medullary bone formation was lower in BSP−/−
mice in comparison to wild type in a marrow ablation model [18]. Moreover, both the adhesion and
chemotactic migration of human umbilical vein endothelial cells (HUVECs) were promoted by BSP in a
dose-dependent manner, which highlights the role of BSP in ανβ3 integrin-mediated angiogenesis [19].
Via its hydroxyapatite binding site, BSP can be bound to hydroxyapatite, and is therefore capable of
inducing a hydroxyapatite cluster formation [20,21]. We observed an increased calcium deposition
of hOBs after 21 days in medium supplemented with BSP [12]. All of these favorable characteristics
highlight the potential of BSP as a surface modifier that could enhance the osseointegration of bone
substitutes. Although these BSP properties sound promising, it is still uncertain whether the BSP
coating of CPC scaffolds is of benefit to bone ingrowth in vivo. The purpose of our study was to
examine whether BSP-coated CPC scaffolds are superior to uncoated scaffolds in terms of bone
formation in a critical-size calvarial defect in mice.
2. Materials and Methods
2.1. Scaffold Preparation and Coating
Three-dimensional printed CPC scaffolds (2.7-mm diameter, 1.8-mm height) with interconnecting
pores were purchased from INNOTERE GmbH (Radebeul, Germany). A mixture of eight parts of
CPC powder containing a-tricalciumphosphate (a-TCP, 60%), dicalcium phosphate anhydride (DCP,
26%), calcium carbonate (CaCO3, 10%) and precipitated hydroxyapatite (HA, 4%) and two parts of
carrier liquid were used for printing the scaffolds with a final Ca/P ratio of 1.5. Details concerning
scaffold preparation or the printing process can be found in specified publications [8,22]. Prior to
use, the scaffolds were solidified by incubating the cement in 0.9% sodium chloride for 28 days
followed by intense rinsing in deionized water, drying, and gamma irradiation. Lode et al. proved
the cytocompatibility of the scaffolds in 2014 via cell culture experiments performed with human
mesenchymal stem cells (hMSCs) [8]. The scaffolds’ specific surface area was 12 m2/g. The ratio
of macroporosity reached 50%, with pore sizes up to 0.069 mm2 in the transverse plane, and up
to 0.173 mm2 in the side wall of the scaffolds (with a double-strand design in the z-axis). Scaffold
coating was conducted according to a previously described protocol [13]. First, the scaffolds were
preincubated for 24 h in Dulbecco’s Modified Eagle Medium (DMEM)/Ham’s F-12 medium (Gibco®,
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Life Technologies, Grand Island, NY, USA) without any supplements at 37 ◦C to ensure efficient
conditioning (ion exchange and binding of serum proteins to the CPC surface). This step was
followed by incubation with BSP solution (200 µg/mL; Immundiagnostik, Bensheim, Germany)
or PBS (phosphate-buffered saline; Sigma-Aldrich, Steinheim, Germany) under mechanical stirring
at 8 ◦C for 24 h. Thereafter, the scaffolds were washed two times with PBS, dried under laminar air
flow, and stored at 8 ◦C until scaffold implantation. Successful BSP coating with this method and
observations of BSP release were performed in in vitro studies in our laboratory [13]. For qualitative
coating evaluation, the scaffolds were coated with a fluorescein-coupled BSP solution. A fluorescein
conjugation system (Lightning-Link® Fluorescein Conjugation Kit, Innova Biosciences, Cambridge, UK)
was used according to the manufacturer’s instructions prior to the coating step with BSP. The scaffolds
were rinsed after the coating step with PBS, dried, cut and visualized with the EVOS® microscope
(Life Technologies, Carlsbad, CA, USA).
2.2. Study Design
This study was approved by the local ethics committee (G 15-1-050). National regulations for
the care and use of laboratory animals were respected at all times. Forty-five female C57BL/6NRj
mice with an average age of six weeks were divided into three groups (BSP-coated scaffolds, uncoated
scaffolds (treatment with PBS), and negative control (NC, no scaffold implantation)). For evaluation of
direct ossification, a critically sized calvarial defect model was performed in mice [23]. Five mice were
housed per cage (type 2, with filter hood) under light and dark cycles (12 h) with free cage activity and
drinking water as well as food ad libitum.
2.3. Anaesthesia and Surgical Procedure
One day prior to the surgical procedure, the drinking water was supplemented with tramadol
(1 mg/mL; Ratiopharm, Ulm, Germany). Mice were anaesthetized with an intraperitoneal injection of
midazolam (5 mg/kg body weight), medetomidin (500 µg/kg) and fentanyl (50 µg/kg). The animal’s
scalps were prepped with Braunol 7.5%, followed by a midsagittal skin incision and exposure of the
parietal bone. On each side of the sagittal suture, a bone defect with a 2.7-mm diameter was carefully
set with a drill (Hager & Meissinger, Neuss, Germany) using saline water (0.9%; Braun, Melsungen,
Germany) for irrigation. Care was taken to avoid lesions of dura mater and superior sagittal sinus.
Bone debris was removed under saline irrigation. In the treatment groups, either a BSP-coated scaffold
or an uncoated scaffold was implanted in press-fit technique, where applicable (Figure 1). In some
cases, press-fit anchoring was not achievable, and the scaffold had some mobility in the bone defect.
Defects in the negative control were left empty. The skin was closed with sutures. Drinking water was
supplemented with tramadol (1 mg/mL) postoperatively for up to five days.
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Mice were killed by CO2 inhalation after eight weeks of observation. The fur from the head
and neck region was removed, followed by decapitation. Afterwards, the skull was fixed with
4.5% formaldehyde solution (Carl-Roth, Karlsruhe, Germany) for a minimum of three days for
further analysis.
2.4. Micro Computed Tomography (µCT) Analyses
For µCT measurements, the fixed samples were analyzed with 70 kV and 114 µAmp using the µCT
40 (Scanco Medical, Brüttisellen, Switzerland). The voxel size was set to 30 µm. In the scaffold groups,
only defects with direct bone–implant contact (BIC) were included in the statistical data evaluation, as we
did not find any bone formation in the absence of direct bone-implant contact (data not shown). For bone
thickness examination, this led to a number of evaluable defects of n = 10 (CPC), n = 8 (CPC + BSP), and
a size-matched negative control of n = eight defects. In BV/TV measurements, the number of evaluable
defects was n = 11 (CPC), n = 9 (CPC + BSP), and a negative control of n = 26 defects.
2.5. Measurements of Bone Thickness at the Bone–Implant Interface
Bone regeneration at the margins of the defect was analyzed by measurement of bone thickness.
Four opposing locations were determined in a horizontal µCT section (Figure 2A). Measurements were
carried out in coronal µCT cuts (Figure 2B).
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Figure 2. Transverse (A) and coronal (B) µCT cuts of bone defect and scaffold. Bone thickness (green
circles) was measured at four distinct locations (brown circles) per defect.
2.6. Bone Volume/Total Volume Ratio
Bone volume/total volume (BV/TV) ratios were analyzed using Image J software [24,25] with the
BoneJ plugin [26]. For bone volume (BV) evaluation, the grey-value CT data was converted with the
help of thresholds into two binaries. Due to different Hou sfield units (scaffold 6695 and bone 3223),
a clear separation between bone and scaffold was possible (Figure 2). The first binary consisted of
both bone and scaffold data. The second binary included the scaffolds’ data only. Next, the scaffolds’
binary was subtracted from the combined binary. As a result, a ew “bone only” binary was gained
for further BV/TV analyses. The samples were rearranged using the Alig Stacks plugin, followed
by analysis with the BoneJ plugin. A cylinder with a diameter of 2.5 mm and a height of 2.2 mm
was defined as the region of interest (ROI) and represented the dimensions of the total volume (TV).
In order to evaluate bone ingrowth into the scaffolds center, smaller diameters (2 m , 1.5 mm, 1 mm,
and 0.5 mm) were analyzed as well.
2.7. Histological Analysis
For histological analysis, the samples were decalcified with a 10% ethylenediaminetetraacetic acid
(EDTA, Applichem, Darmstadt, Germany) solution buffered with tris(hydroxymethyl)aminomethane
(TRIS, Applichem, Darmstadt, Germany) for three weeks. Then, the tissue was cut close to
the ROI, dehydrated, and embedded in paraffin using the SAKURA VIP E150 Tissue Processor
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(Miles Scientific, Naperville, IL, USA). The embedded samples were cut into 5-µm thick slices.
Every fifth section was stained with hematoxylin (Polysciences Europe, Eppelheim, Germany) and
eosin (HE; Carl-Roth, Karlsruhe, Germany). For HE staining, samples were deparaffinized with xylene
(3× 10 min; Applichem, Darmstadt, Germany) and rehydrated using a downstream isopropyl alcohol
(IPA; Carl-Roth, Karlsruhe, Germany) series (2 × 5 min 100% IPA, 2 × 5 min 96% IPA, 1 × 5 min
70% IPA, 1 × 5 min 50% IPA), which finished in distilled water. Next, the slices were stained with
hematoxylin according to Gill (7 min; Polysciences Europe, Eppelheim, Germany) and eosin (3 min;
Carl-Roth, Karlsruhe, Germany), followed by an upward IPA series, xylene incubation (3 × 5 min)
and coverslipping with CytosealTM XYL (Richard-Allan Scientific, San Diego, CA, USA). In addition
to HE staining, Masson–Goldner–Trichrom staining (MGT) staining was performed. Besides nucleus
and cytoplasm stain, this triple stain highlight different types of connective tissue. Distinctions
between bone and connective tissue are apparent by means of different green tones. For MGT
staining, the rehydrated samples were stained with hematoxylin according to Weigert (five minutes;
Carl-Roth, Karlsruhe, Germany), ponceau-acid fuchsin (10 min; Sigma-Aldrich, Steinheim, Germany),
phosphotungstic acid–orange G (10 min; Carl-Roth, Karlsruhe, Germany) and 0.2% light green (10 min;
Chroma-Gesellschaft, Köngen, Germany). Differentiation occurred with 1% acetic acid (circa 30 s)
between the individual stages.
2.8. Immunohistological Analysis
Hydrated samples were incubated with protein kinase K (Dako, Hamburg, Germany) for
enzymatic antigen retrieval for 10 min, followed by two washing steps (every step five minutes)
in PBS. Endogenous peroxidases were blocked with 3% hydrogen peroxide (Merck, Darmstadt,
Germany), followed by several washing steps with PBS and the prevention of unspecific antibody
binding with 10% horse serum for 30 min. Incubation with the first antibody was performed over
night at 4 ◦C. Osteopontin (OPN; Abcam, Cambridge, UK), von Willebrand factor (vWF; Life Span
Biosciences, Seattle, WA, USA) and platelet endothelial cell adhesion molecule-1 (PECAM-1; Abcam,
Cambridge, UK) were assessed. The controls were incubated in PBS with 1% bovine serum albumin
(BSA) without antibody (no AB). On the next day, two washing steps with PBS (each five minutes)
were performed, followed by incubation with a biotinylated link (Dako, Hamburg, Germany) for
10 min, 5 min of PBS twice, and 10 min of streptavidin–horseradish peroxidase (HRP, Dako, Hamburg,
Germany). Next, another two washing steps (five minutes) with PBS followed. Incubation with
3,3′-diaminobenzidine (DAB) substrate–chromogen (Dako, Hamburg, Germany) was controlled
microscopically. The conversion from 3,3′-diaminobenzidine (DAB) into a brown-colored precipitate
was stopped with distilled water. Finally, the sections were counterstained with hematoxylin according
to Gill.
2.9. Statistical Analyses
SPSS 23.0 (IBM, Chicago, IL, USA) software was used for statistical analyses. Quantitative results
were presented as means ± standard deviation. Data were analyzed with a Welch-ANOVA, followed
by Games–Howell post-hoc analysis. A p-value < 0.05 was considered statistically significant. Boxplots
were presented with medians and quartiles.
3. Results
3.1. Qualitative Evaluation of BSP Coating
BSP coating was performed with a fluorescein coupled solution to control the success of the
coating process. The stability of the coating was indicated by an intensive green fluorescence that
persisted after several washing steps with PBS (Figure 3). In order to evaluate the depth of the
penetration of the coating solution, the scaffolds were cut vertically and horizontally. As expected,
fluorescence intensity was less pronounced in the middle section of the scaffolds.
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3.3. Bone Volume/Total Volume (BV/TV)
In addition to the measurement of bone thickness at the defect´s margins, calculation of new bone
formation within the defect was performed (Figure 5).
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Figure 5. Three-di ensional vie of ne ly for ed bone ithin the region of interest (R I) fro the
top vie (upper row), the lateral view (middle row), and the oblique view (lower row).
Bone for ation can be expressed as a bone fraction or bone volume/total volume (BV/TV).
In order to be able to make a statement about bone ingro th into the scaffold, e evaluated not only
the total scaffold (dia eter of R I: 2.5 , height of 2.2 ), but also the cylindrical R Is ith the
sa e height but s aller dia eters (1.0 , 1.5 , and 2.0 , Figure 6). In the very center of the
scaffold (which was defined as a cylinder with a diameter of 1.0 mm and a height of 2.2 mm), we could
notice a BV/TV of 0.6 ± 0.5% (CPC) and 1.0 ± 0.8% (CPC + BSP) versus 0.009 ± 0.04% in the control.
In the total scaffold, BV/TV was 0.9 ± 0.5% (CPC), 1.3 ± 0.5% (CPC + BSP), and 0.2 ± 0.3% (no CPC),
respectively. Although we observed a tendency towards increased bone ingrowth in the outer layers
of the scaffolds and a significant difference between both scaffold groups and the control (no CPC),
we did not detect a significantly increased bone growth in the BSP-coated scaffolds compared to the
uncoated scaffolds (Figure 6).
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Figure 6. Boxplot of the bone fraction (bone volume (BV)/total volume (TV) ratio) after eight weeks.
The core of the scaffold is represented by a virtual cylinder with a diameter of 1.0 mm, whereas the
total scaffold is represented by a diameter of 2.5 mm. Therefore, different diameters illustrate bone
ingrowth into the different layers of the scaffold. Statistically significant differences are labeled by
asterisks (*: p < 0.05, **: p < 0.01, ***: p < 0.001).
3.4. Histology
3.4.1. HE Stainings
Histological assessments were made to complete the picture of scaffold integration and new bone
formation. Bone ingrowth was the most pronounced in the BSP-coated scaffolds. The inner rows of the
scaffold were tightly covered with bone in the BSP group, whereas the uncoated scaffolds developed
new bone predominantly in the peripheral areas. In the negative control, the osseous defect was
covered with fibrous tissue only (Figure 7).
3.4.2. Masson-Goldner-Trichrom (MGT) Staining
MGT staining the CPC scaffolds without BSP coating displayed newly formed bone in direct
contact with the material, while the p res between the indivi ual strands consisted mainly of
connective tissue. In contrast, the BSP coating led not only to bone formation in direct contact
with the material, but also inside the pores, as well as above and below the scaffolds (Figure 7). Bone
inside the scaffolds’ pores consisted of dense and trabecular parts in t e BSP group and resembled the
natural calvarial bone, whereas the trabecular parts in the uncoated scaffolds were u common. In the
negative control, the defect was filled with fibrous tissue, and bone formation could only be observed
at the very margins of the defect (Figure 7, no CPC).
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endothelial cell adhesion molecule (PECAM-1 or cluster of differentiation 31 (CD31)) and von 
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Figure 7. Masson-Goldner-Trichrom (MGT) and hematoxylin-eosin (HE) stainings after eight weeks. New
bone growth (green arrows). Trabecular bone structure (green asterisks). BT: calvarial bone tissue at the
margins of the defect. BV: blood vessel. FT: fibrous tissue. S: scaffold. BSP-coated scaffolds (CPC + BSP)
presented with new bone growth also above and below the scaffold.
3.4.3. Im unohistological Staining
Immunohistological staining was performed for osteopontin (OPN), which plays a pivotal role in
the regulation of mineralization within the extracellular matrix (ECM) of bone [27]. OPN is scarcely
found in the group without CPC, and only at the margins of the bone defect (Figure 8). In the CPC
group, we observed a greater amount of OPN+-cells that were situated around the islets of new bone.
OPN+-cells occurred in abundance in the CPC + BSP group, where they enclosed in thick layers
not only the newly formed bone, but also the adjoining soft tissue. Stainings of platelet endothelial
cell adhesion molecule (PECAM-1 or cluster of differentiation 31 (CD31)) and von Willebrand factor
(vWF) were performed to demonstrate the presence of endothelial cells after blood vessel formation.
While blood vessels were hardly detectable in the control (no CPC), the histological sections indicated
a thorough neovascularization of uncoated and BSP-coated scaffolds (Figure 8).
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osseointegration at the scaffold–bone interface [30]. However, the vascularization of bone substitutes 
is the mainstay of scaffold remodeling [31]. Particularly in larger scaffolds, vessel penetration 
assures sufficient oxygen and nutrient supply for cells, even in the scaffold’s center. Therefore, both 
the improvement of bone formation and angiogenesis are of main interest. BSP coating could fill this 
gap, as BSP is able to induce hydroxyapatite cluster formation and attract both osteoblasts as well as 
endothelial cells via their ανβ3-receptor [19–21]. A coating concentration of 200 µg/mL has proven to 
be advantageous for cell viability and the gene expression of primary human osteoblasts (hOBs) in 
our in vitro studies [12,13]. Thus, this concentration was chosen for our in vivo model. In our 
Figure 8. Immunohistological analysis of endothelial and osteoblast cell markers (von Willebrand
factor (vWF), platelet endothelial cell adhesion molecule-1 (PECAM-1), and osteopontin (OPN)). Black
arrows indicate positive staining (3,3′-diaminobenzidine (DAB) precipitate). Blood vessels in the
scaffold’s pores were strongly positive for PECAM-1 and vWF, and were notably pronounced in the
BSP group. Cells in contact with newly formed bone were positive for OPN, particularly in scaffolds
with BSP coating. There were no stained areas in the sections with no antibody (no AB). FT: fibrous
tissue. BT: bone tissue. S: scaffold.
4. isc ssio
he integration of bone substitutes into the local bone stock is a complex process. On the protein
level, the initial host response is affected by the scaffold’s material and the first layer of proteins on
an implant [28,29]. The activation, migration, and differentiation of osteoprogenitor cells are key
elements in the synthesis of the extracellular matrix, and are thus esse tial for osseointegration at
the scaffold–bo e interface [30]. However, the vascularization of bone substitutes is the mainstay of
scaffold remodeling [31]. Particularly i larger scaffolds, vessel penetration assures sufficient oxyge
and nutrient supply for cells, even i the scaffold’s center. Therefore, both the improvement of bone
formation and angiogenesis are of mai interest. BSP coating could fill this gap, as BSP is able to induce
hydroxyapatite cluster formation and attract both osteoblasts as well as endothelial cells via their
ανβ3-receptor [19–21]. A coating concentration of 200 µg/mL has proven to be advantageous for cell
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viability and the gene expression of primary human osteoblasts (hOBs) in our in vitro studies [12,13].
Thus, this concentration was chosen for our in vivo model. In our previous works, we were able to show
that after an initial burst, CPC scaffolds were capable of binding and retaining BSP via physisorption.
During the first 48 h after coating, slow release kinetics with a cumulative release of 0.8–28 µg were
observed. This release pattern was similar to that of BSA (bovine serum albumin)-coated CPCs [32,33].
Our hypothesis was that the BSP coating of CPC scaffolds might lead to an increased formation of
bone in comparison to untreated scaffolds in vivo. Based on measurements of bone thickness and
the BV/TV ratio, we provide sufficient evidence that BSP-coated CPC scaffolds are not superior to
uncoated scaffolds in terms of bone formation. The increase in the mean values of the measured
parameters after BSP coating is not statistically significant. Bone thickness as well as total bone volume
was significantly higher in both scaffold groups in comparison to the negative control. Histological
stainings showed a more extensive coverage and infiltration of BSP-coated scaffolds with new bone
when matched with uncoated scaffolds. The immunohistological detection of vWF, PECAM-1, and
OPN displayed the formation of blood vessels in scaffolds that appeared to be more pronounced in
the BSP group. Particularly in scaffolds with BSP coating, OPN-positive osteoblastic cells flocked in
multilayers to the newly formed osteoid.
These findings are consistent with our previous in vitro experiments, where we detected increased
osteoblastic viability, morphological hOB differentiation, and the spreading of primary human
osteoblasts on BSP-coated CPC scaffolds [13]. Graf et al. reported on the increased attraction
and attachment of human bone-derived cells and an enhanced transforming growth factor beta
(TGF-ß)-expression on BSP-coated hydroxyapatite-based titanium implants in vitro [34]. In another
in vitro study, Hilbig et al. found that pre-coating with BSP improved the proliferation of human
osteoblasts on a smooth glimmer more than on titanium with hydroxyapatite ceramic [35]. In vivo
experiments investigating the effect of BSP-coated CPC scaffolds on bone healing are scarce. BSP
coating did not have an apparent effect on bone formation following the ectopic implantation of
β-tricalcium phosphate scaffolds in nude mice [36]. However, when collagen-binding (CB) peptides
derived from BSP were applied to a hydroxyl apatite scaffold, bone growth was significantly stimulated
in an in vivo rabbit calvarial defect within two weeks [37]. Chan et al. used BSP-coated polymer
networks instead of CPC scaffolds and found enhanced attachment and spreading, but no effect
on the proliferation of MC3T3-E1 cells in vitro [38]. BSP–collagen scaffolds stimulated osteoblast
differentiation, bone growth, and vascularization in vivo in a rat calvarial defect model [39]. In a rat
model, BSP–collagen scaffolds induced early mineral deposition and resulted in more newly formed
bone in comparison to collagen scaffolds in 8-mm calvarial bone defects [40].
A possible limitation of our study was that an eight-week-period from implantation till µCT
assessment may be too long for investigating the differences between the scaffolds’ potential for
osteoconduction and osteoinduction in the early phase of bone regeneration. Since uncoated scaffolds
are shown to have noticeable bone ingrowth after eight weeks, a shorter observation period might
have allowed detecting a possible increase in the bone formation rate through BSP coating. The bone
formation rate is of main interest: larger scaffolds (as used in large animal models or human beings)
could be interpenetrated in a shorter time span, and the weight bearing of extremities could start
earlier. Even if there is a positive effect of BSP coating on the new formation of bone, the sample size in
our study might have been too small to provide the needed evidence. An anchoring of the scaffold in
the calvarial defect (e.g. with fibrin glue or through a conical shape of the scaffold) might have led to a
higher rate of bone–implant contacts due to less scaffold mobility, and finally, to less exclusions from
analyses resulting in a sample size that is high enough to detect statistically significant differences.
Although our results are in general agreement with previous findings, we were not able to prove
the superiority of BSP coating over uncoated scaffolds in the murine calvarial model eight weeks
after implantation. We found vessel formation and the formation of new bone in both scaffold groups
(BSP coated and uncoated scaffolds). The advantage of BSP coating over uncoated scaffolds may be
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provided in the early stages after scaffold implantation. Thus, further investigations are required to
determine the time dependency of vessel and bone formation early after scaffold implantation.
5. Conclusions
In our mouse calvarial defect model, coating CPC scaffolds with BSP showed a tendency
towards an increased bone formation in comparison to uncoated CPC scaffolds in bone fractions,
BV/TV, and histological sections, but the observed effects were not statistically significant after
eight weeks. These parameters differed significantly between both scaffold groups and the negative
control. Both BSP-coated and uncoated CPC scaffolds revealed massive bone ingrowth, albeit bone
growth in histological stainings was found to be more extensive than in the former. The structure
of the newly formed bone resembled that of natural trabecular bone when BSP was applied to the
scaffolds. Immunohistological staining presented that vessel formation and OPN+ cell population
was pronounced in the BSP group. Our results demonstrate the feasibility of BSP coating, although
exceptional effects on bone growth were not detectable. However, further studies could deal with
the influence of the scaffolds’ material on the effect of BSP, and should focus on the investigation of
spatio-temporal patterns of bone formation and vascular ingrowth in vivo.
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